REMARKS/ARGUMENTS

Reconsideration of this application and entry of the foregoing amendment are respectfully requested.

The specification has been amended to include the Sequence Listing submitted herewith on separate sheets. Applicants submit that entry of the Sequence Listing does not raise the issue of new matter. The computer readable copy of the Sequence Listing submitted herewith is the same as the attached paper copy of that Listing.

This application is submitted to be in condition for allowance and a Notice to that effect is requested.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: Mary J. Wilson

Mary J. Wilson
Reg. No. 32,955

MJW:tat
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

Notice to Comply	Application No. 10568691	Applicant(s) BAWDEN ET AL.	
	Examiner Alana M.. Harris, Ph.D.	Art Unit 1643	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).

☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

☐ 7. Other:

Applicant Must Provide:

☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

☒ An initial or substitute paper copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.**

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-0731 or (571) 272-0951
For CRF Submission Help, call (571) 272-2510
PatentIn Software Program Support
Technical Assistance.1-866-217-9197 or 703-305-3028 or 571-272-6845
PatentIn Software is Available At www.USPTO.gov

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

/Alana M. Harris, Ph.D./ **Primary Examiner, Art Unit 1643**	

EQUENCE LISTING

<110> Chroma Therapeutics Limited

Bawden, Lindsay J

Bone, Elizabeth A

Drummond, Alan H

Needham, Lindsey A

<120> Detection of Histone Modification in Cell-free Nucleosomes

<130> NRSCP6244818

<140> PCT/GB2004/003564

<141> 2004-08-18

<150> GB 0319376.0

<151> 2003-08-18

<160> 16

<170> PatentIn version 3.1

<210> 1

<211> 8

<212> PRT

<213> Homo sapiens

<220>

<223> Example of peptide which may be used to generate modified histone specific antibodies: H3 lys 4 (Me)

<220>

<221> MOD_RES

<222> (4)..(4)

<223> METHYLATION

<400> 1

Ala Arg Thr Lys Gln Thr Ala Arg
1 5

<210> 2

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<223> Example of peptide which may be used to generate modified histone specific antibodies: H4 arg 3 (Me)

<220>

<221> MOD_RES

<222> (3)..(3)

<223> METHYLATION

<400> 2

Ser Gly Arg Gly Lys
1 5

<210> 3

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<223> Example of peptide which may be used to generate modified histone

specific antibodies: H4 lys 5 (Ac)

<220>

<221> MOD_RES

<222> (5)..(5)

<223> ACETYLATION

<400> 3

Ser Gly Arg Gly Lys
1 5

<210> 4

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<223> Example of peptide which may be used to generate modified histone specific antibodies: H4 arg 3 (Me)/lys 5 (Ac)

<220>

<221> MOD_RES

<222> (3)..(3)

<223> METHYLATION

<220>

<221> MOD_RES

<222> (5)..(5)

<223> ACETYLATION

<400> 4

Ser Gly Arg Gly Lys
1 5

<210> 5

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<223> Example of peptide which may be used to generate modified histone specific antibodies: H4 Ser 2(phos)/Arg 3 (me)/Lys 5 (Ac)

<220>

<221> MOD_RES

<222> (1)..(1)

<223> PHOSPHORYLATION

<220>

<221> MOD_RES

<222> (3)..(3)

<223> METHYLATION

<220>

<221> MOD_RES

<222> (5)..(5)

<223> ACETYLATION

<400> 5

Ser Gly Arg Gly Lys
1 5

<210> 6

<211> 9

<212> PRT

<213> Homo sapiens

<220>

<223> Example of peptide which may be used to generate modified histone specific antibodies: H3 lys 9 (Me)

<220>

<221> MOD_RES

<222> (5)..(5)

<223> METHYLATION

<400> 6

Gln Thr Ala Arg Lys Ser Thr Gly Val
1 5

<210> 7

<211> 11

<212> PRT

<213> Homo sapiens

<220>

<223> Example of peptide which may be used to generate modified histone specific antibodies: H2B ser 14 (Phos)

<220>

<221> MOD_RES

<222> (9)..(9)

<223> PHOSPHORYLATION

<400> 7

Ser Ala Pro Ala Pro Lys Lys Gly Ser Lys Lys
1 5 10

<210> 8

<211> 10

<212> PRT

<213> Homo sapiens

<220>

<223> Example of peptide which may be used to generate modified histone specific antibodies: H3 lys 27 (Me)

<220>

<221> MOD_RES

<222> (4)..(4)

<223> METHYLATION

<400> 8

Ala Ala Arg Lys Ser Ala Pro Val Cys Gly
1 5 10

<210> 9

<211> 11

<212> PRT

<213> Homo sapiens

<220>

<223> Example of peptide which may be used to generate modified histone specific antibodies: H3 lys 36 (Me)

<220>

<221> MOD_RES

<222> (5)..(5)

<223> METHYLATION

<400> 9

Ser Gly Gly Val Lys Lys Pro His Lys Cys Gly
1 5 10

<210> 10

<211> 10

<212> PRT

<213> Homo sapiens

<220>

<223> Example of peptide which may be used to generate modified histone specific antibodies: H4 lys 20 (Me)

<220>

<221> MOD_RES

<222> (4)..(4)

<223> METHYLATION

<400> 10

Arg His Arg Lys Ile Leu Arg Asp Cys Gly
1 5 10

<210> 11

<211> 135

<212> PRT

<213> Homo sapiens

<400> 11

Ala Arg Thr Lys Gln Thr Ala Arg Lys Ser Thr Gly Gly Lys Ala Pro
1 5 10 15

Arg Lys Gln Leu Ala Thr Lys Ala Ala Arg Lys Ser Ala Pro Ala Thr
20 25 30

Gly Gly Val Lys Lys Pro His Arg Tyr Arg Pro Gly Thr Val Ala Leu
35 40 45

Arg Glu Ile Arg Arg Tyr Gln Lys Ser Thr Glu Leu Leu Ile Arg Lys
50 55 60

Leu Pro Phe Gln Arg Leu Val Arg Glu Ile Ala Gln Asp Phe Lys Thr
65 70 75 80

Asp Leu Arg Phe Gln Ser Ser Ala Val Met Ala Leu Gln Glu Ala Ser
85 90 95

Glu Ala Tyr Leu Val Gly Leu Phe Glu Asp Thr Asn Leu Cys Ala Ile
100 105 110

His Ala Lys Arg Val Thr Ile Met Pro Lys Asp Ile Gln Leu Ala Arg
115 120 125

Arg Ile Arg Gly Glu Arg Ala
130 135

<210> 12

<211> 102

<212> PRT

<213> Homo sapiens

<400> 12

Ser Gly Arg Gly Lys Gly Gly Lys Gly Leu Gly Lys Gly Gly Ala Lys
1 5 10 15

Arg His Arg Lys Val Leu Arg Asp Asp Ile Gln Gly Ile Thr Lys Pro
20 25 30

Ala Ile Arg Arg Leu Ala Arg Arg Gly Gly Val Lys Arg Ile Ser Gly
35 40 45

Leu Ile Tyr Glu Glu Thr Arg Gly Val Leu Lys Val Phe Leu Glu Asn
50 55 60

Val Ile Arg Asp Ala Val Thr Tyr Thr Glu His Ala Lys Arg Lys Thr
65 70 75 80

Val Thr Ala Met Asp Val Val Tyr Ala Leu Lys Arg Gln Gly Arg Thr
85 90 95

Leu Tyr Gly Phe Gly Gly
100

<210> 13

<211> 129

<212> PRT

<213> Homo sapiens

<400> 13

Ser Gly Arg Gly Lys Gln Gly Gly Lys Ala Arg Ala Lys Ala Lys Thr
1 5 10 15

Arg Ser Ser Arg Ala Gly Leu Gln Phe Pro Val Gly Arg Val His Arg

```
            20                  25                  30

Leu Leu Arg Lys Gly Asn Tyr Ala Glu Arg Val Gly Ala Gly Ala Pro
        35                  40                  45

Val Tyr Leu Ala Ala Val Leu Glu Tyr Leu Thr Ala Glu Ile Leu Glu
    50                  55                  60

Leu Ala Gly Asn Ala Ala Arg Asp Asn Lys Lys Thr Arg Ile Ile Pro
65                  70                  75                  80

Arg His Leu Gln Leu Ala Ile Arg Asn Asp Glu Glu Leu Asn Lys Leu
                85                  90                  95

Leu Gly Lys Val Thr Ile Ala Gln Gly Gly Val Leu Pro Asn Ile Gln
            100                 105                 110

Ala Val Leu Leu Pro Lys Lys Thr Glu Ser His His Lys Ala Lys Gly
        115                 120                 125

Lys
```

<210> 14

<211> 125

<212> PRT

<213> Homo sapiens

<400> 14

```
Pro Glu Pro Ser Lys Ser Ala Pro Ala Pro Lys Lys Gly Ser Lys Lys
1               5                   10                  15

Ala Ile Thr Lys Ala Gln Lys Lys Asp Gly Lys Lys Arg Lys Arg Ser
            20                  25                  30

Arg Lys Glu Ser Tyr Ser Ile Tyr Val Tyr Lys Val Leu Lys Gln Val
        35                  40                  45

His Pro Asp Thr Gly Ile Ser Ser Lys Ala Met Gly Ile Met Asn Ser
    50                  55                  60

Phe Val Asn Asp Ile Phe Glu Arg Ile Ala Gly Glu Ala Ser Arg Leu
65                  70                  75                  80

Ala His Tyr Asn Lys Arg Ser Thr Ile Thr Ser Arg Glu Ile Gln Thr
                85                  90                  95

Ala Val Arg Leu Leu Leu Pro Gly Glu Leu Ala Lys His Ala Val Ser
            100                 105                 110

Glu Gly Thr Lys Ala Val Thr Lys Tyr Thr Ser Ser Lys
        115                 120                 125
```

<210> 15

<211> 142

<212> PRT

<213> Homo sapiens

<400> 15

```
Ser Gly Arg Gly Lys Thr Gly Gly Lys Ala Arg Ala Lys Ala Lys Ser
1               5                  10                  15

Arg Ser Ser Arg Ala Gly Leu Gln Phe Pro Val Gly Arg Val His Arg
            20                  25                  30

Leu Leu Arg Lys Gly His Tyr Ala Glu Arg Val Gly Ala Gly Ala Pro
        35                  40                  45

Val Tyr Leu Ala Ala Val Leu Glu Tyr Leu Thr Ala Glu Ile Leu Glu
    50                  55                  60

Leu Ala Gly Asn Ala Ala Arg Asp Asn Lys Lys Thr Arg Ile Ile Pro
65                  70                  75                  80

Arg His Leu Gln Leu Ala Ile Arg Asn Asp Glu Glu Leu Asn Lys Leu
                85                  90                  95

Leu Gly Gly Val Thr Ile Ala Gln Gly Gly Val Leu Pro Asn Ile Gln
            100                 105                 110

Ala Val Leu Leu Pro Lys Lys Thr Ser Ala Thr Val Gly Pro Lys Ala
        115                 120                 125

Pro Ser Gly Gly Lys Lys Ala Thr Gln Ala Ser Gln Glu Tyr
    130                 135                 140
```

<210> 16

<211> 135

<212> PRT

<213> Homo sapiens

<400> 16

```
Ala Arg Thr Lys Gln Thr Ala Arg Lys Ser Thr Gly Gly Lys Ala Pro
1               5                  10                  15

Arg Lys Gln Leu Ala Thr Lys Ala Ala Arg Lys Ser Ala Pro Ser Thr
            20                  25                  30
```

```
Gly Gly Val Lys Lys Pro His Arg Tyr Arg Pro Gly Thr Val Ala Leu
       35                  40                  45

Arg Glu Ile Arg Arg Tyr Gln Lys Ser Thr Glu Leu Leu Ile Arg Lys
    50                  55                  60

Leu Pro Phe Gln Arg Leu Val Arg Glu Ile Ala Gln Asp Phe Lys Thr
65                  70                  75                  80

Asp Leu Arg Phe Gln Ser Ala Ala Ile Gly Ala Leu Gln Glu Ala Ser
                85                  90                  95

Glu Ala Tyr Leu Val Gly Leu Phe Glu Asp Thr Asn Leu Cys Ala Ile
            100                 105                 110

His Ala Lys Arg Val Thr Ile Met Pro Lys Asp Ile Gln Leu Ala Arg
        115                 120                 125

Arg Ile Arg Gly Glu Arg Ala
    130                 135
```